Margaret was sixty-six when she reached for something on a high shelf, heard a pop, and spent the next three months managing a vertebral compression fracture. The fracture happened during routine daily activity — not a fall, not an accident. Her DXA scan showed T-score of -2.8 at the lumbar spine, confirming osteoporosis. Her primary care physician prescribed alendronate and calcium supplements. What her physician did not do: investigate why a sixty-six-year-old woman had a T-score this low. No vitamin D level measured. No parathyroid hormone. No workup for secondary causes of bone loss. No dietary assessment. No review of her twenty-year history of proton pump inhibitor use, which impairs calcium absorption. No discussion of the resistance training evidence that builds bone mineral density more effectively than bisphosphonate therapy alone. Margaret started alendronate, took her calcium supplement, and waited to see whether the medication would protect her remaining bone. The comprehensive approach that could have addressed the multiple modifiable causes of her bone loss was never offered.
Osteoporosis — defined by World Health Organization criteria as bone mineral density T-score at or below -2.5 standard deviations from peak young adult bone density — affects approximately 10 million Americans and is present in an additional 44 million with low bone density (osteopenia, T-score between -1 and -2.5). Hip fracture, the most serious complication, carries 20-30% one-year mortality and 50% permanent functional limitation in those who survive. Vertebral fractures — the most common osteoporotic fracture — cause chronic back pain, loss of height, kyphosis, and impaired respiratory function. These consequences are largely preventable through bone density optimization starting in childhood and maintained through adulthood. But the window for maximum benefit is early, decades before the fractures that prompt the first DXA scan.
Bone Biology: The Dynamic Tissue Most People Misunderstand
Bone is not static structural material. It’s a metabolically active tissue continuously remodeling at rates that vary by site, age, hormonal status, and mechanical loading. The two key cell types driving bone remodeling: osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). In healthy bone, these are coupled — osteoblast activity is stimulated by osteoclast resorption through coupling factors including RANKL/OPG signaling, IGF-1, and TGF-beta. When resorption exceeds formation over sustained periods — as occurs with estrogen deficiency, vitamin D deficiency, calcium insufficiency, physical inactivity, or corticosteroid use — net bone loss results in the progressive trabecular thinning and cortical porosity that define osteoporosis.
The RANK/RANKL/OPG system is the central molecular regulator of bone remodeling and the target of the biologic medication denosumab. Receptor activator of nuclear factor kB (RANK) on osteoclasts is activated by its ligand RANKL (produced by osteoblasts), stimulating osteoclast differentiation and bone resorption. Osteoprotegerin (OPG), also produced by osteoblasts, acts as a decoy receptor for RANKL, blocking this activation and reducing resorption. The RANKL/OPG ratio determines the balance between resorption and formation — estrogen, mechanical loading, and PTH all shift this ratio toward OPG dominance (less resorption), while inflammatory cytokines, glucocorticoids, and menopause shift it toward RANKL dominance (more resorption). Dietary and lifestyle interventions that influence inflammation, hormonal status, and mechanical loading directly modulate the RANKL/OPG balance.
Secondary Causes of Bone Loss: What Must Be Excluded
Approximately 40% of postmenopausal women and 60-70% of men with osteoporosis have secondary causes contributing to their bone loss — conditions and medications that drive bone resorption beyond the primary age-related and hormonal mechanisms. Treating osteoporosis without investigating secondary causes is treating the measurement without addressing the mechanism. The major secondary causes that should be excluded in every osteoporosis evaluation:
Vitamin D deficiency: Profoundly common and easily treated. Vitamin D is essential for intestinal calcium absorption and direct osteoblast function. Severe deficiency causes osteomalacia (deficient mineralization) — a distinct condition from osteoporosis that is frequently confused on DXA. Test: 25-OH vitamin D; target 40-60 ng/mL. Every patient with osteoporosis should have vitamin D checked before and during treatment.
Primary hyperparathyroidism: Elevated PTH from parathyroid adenoma or hyperplasia drives osteoclastic bone resorption and is one of the most common secondary causes of bone loss in postmenopausal women. Test: serum calcium (elevated in hyperPTH), PTH. Surgical correction of the adenoma stops the bone loss and partially restores density — a reversible cause of osteoporosis that medication alone cannot adequately address.
Celiac disease: Malabsorption of calcium, vitamin D, and other bone-supporting minerals in celiac disease produces significant bone loss that is partially reversible with strict GFD and nutritional repletion. Bone density in celiac patients correlates with the degree of villous atrophy and the duration of undiagnosed disease. All patients with unexplained low bone density should have celiac antibody screening.
Hyperthyroidism: Excess thyroid hormone directly stimulates osteoclastic bone resorption. Both untreated hyperthyroidism and chronic excessive thyroid hormone supplementation (overtreated hypothyroidism with TSH suppressed below normal) produce bone loss. TSH should be checked in all patients with osteoporosis, and patients on thyroid supplementation should have TSH targeted to the lower end of normal rather than suppressed.
Glucocorticoid use: Long-term corticosteroid therapy (prednisone 5mg daily or equivalent for three or more months) is the most common cause of drug-induced osteoporosis — directly inhibiting osteoblast function and reducing intestinal calcium absorption. Glucocorticoid-induced osteoporosis (GIOP) occurs at higher T-scores (fractures occur at T-scores less negative than in primary osteoporosis) and fractures occur earlier in the course of bone loss. Patients starting long-term corticosteroids require immediate bone protection measures.
The Bone Density Protocol
- Vitamin D optimization to 40-60 ng/mL: The most common modifiable bone density risk factor and the most commonly undertreated. Vitamin D increases intestinal calcium absorption from approximately 15% (deficiency) to 65% (sufficiency) — the difference between adequate calcium delivery to bone and inadequate calcium delivery regardless of dietary intake. Target serum 25-OH vitamin D of 40-60 ng/mL, and expect established deficiency to need a genuine repletion course rather than a token capsule — what it takes varies enough between adults that the test, not a rule of thumb, sets it. Add vitamin K2 in the MK-7 form alongside any substantial vitamin D supplementation, to direct calcium to bone rather than soft tissue. Quarterly monitoring until target achieved, then semi-annual.
- Calcium 1,000-1,200mg daily from food sources primarily: Dietary calcium is more effective and safer than supplemental calcium for bone health. Calcium supplements (calcium carbonate, calcium citrate) have been associated with increased cardiovascular risk in several meta-analyses — the mechanism proposed is transiently elevated serum calcium promoting vascular calcification. Dietary calcium does not produce the same calcium spike and is not associated with cardiovascular risk. Primary food sources: dairy (300mg per serving), canned salmon with bones, sardines, fortified plant milks, leafy greens (kale and bok choy have better calcium bioavailability than spinach due to lower oxalate), almonds. If dietary calcium consistently falls below 1,000mg daily, supplemental calcium with meals (calcium citrate is better tolerated than carbonate and doesn’t require gastric acid) fills the gap.
- Resistance training with progressive overload: The most evidence-based intervention for building and maintaining bone mineral density in adults. Bone responds to mechanical loading — the piezoelectric signals generated by bone deformation during exercise stimulate osteoblast activity. High-impact and high-force activities (jumping, running, weightlifting) are more osteogenic than low-impact activities (swimming, cycling). Watson et al. (Journal of Bone and Mineral Research, 2018) demonstrated that high-intensity resistance training significantly improved bone mineral density at the lumbar spine and femoral neck in osteopenic postmenopausal women. Target: minimum 2-3 sessions weekly of resistance training involving major muscle groups, with progressive load increases as strength improves.
- Protein intake 1.0-1.2g/kg body weight daily: Adequate protein is required for bone matrix synthesis — the collagen framework on which hydroxyapatite calcium phosphate crystals are deposited. Protein malnutrition directly impairs bone formation. Higher protein intake (above 1.0g/kg) is associated with higher bone mineral density in prospective cohort data when calcium intake is adequate. The concern that high protein intake reduces bone density by acidifying the blood and leaching calcium has not been confirmed in clinical trials; the net effect of adequate protein on bone is beneficial when calcium intake is sufficient to neutralize any transient acid load.
- Magnesium: Approximately 60% of body magnesium is stored in bone, where it contributes to hydroxyapatite crystal structure. Magnesium deficiency reduces osteoblast activity and increases osteoclast activity. Population studies consistently show positive associations between dietary magnesium intake and bone mineral density. Magnesium glycinate or malate is preferred for bioavailability and tolerability. Magnesium is co-required with vitamin D for optimal bone health — vitamin D supplementation in magnesium-deficient patients has reduced efficacy because magnesium is required for vitamin D activation.
- Collagen peptide supplementation: Collagen constitutes 90% of bone’s organic matrix — the framework that gives bone its tensile strength and flexibility. Hydrolyzed collagen peptides (10g daily) have been shown in RCTs to increase bone mineral density and reduce bone resorption markers. König et al. (Nutrients, 2018) demonstrated that collagen peptide supplementation significantly increased spinal and hip BMD in postmenopausal women taking calcium and vitamin D compared to calcium and vitamin D alone. The mechanism: collagen peptide fragments stimulate osteoblast activity and collagen synthesis in bone tissue.
- Eliminate or minimize bone-robbing habits: Cigarette smoking directly inhibits osteoblast function and reduces estrogen levels — smokers have 25% lower bone density than non-smokers on average. Heavy alcohol consumption (more than two drinks daily) inhibits osteoblast function, increases cortisol (which promotes bone resorption), and reduces calcium and magnesium absorption. Excessive sodium intake increases urinary calcium excretion — the same mechanism relevant in kidney stones also accelerates bone calcium loss. Proton pump inhibitors impair calcium absorption by reducing gastric acid required for calcium carbonate dissolution; patients who cannot discontinue PPIs should use calcium citrate (which doesn’t require acid for absorption) and monitor bone density more frequently.
- Consider HRT assessment at menopause: Estrogen is the primary hormone protecting bone in women — the accelerated bone loss at menopause (2-3% per year in the first five years) is directly caused by estrogen withdrawal. Hormone replacement therapy prevents this accelerated loss and is the most effective non-pharmaceutical intervention for maintaining bone density in the early postmenopausal years. The risk-benefit assessment of HRT has been substantially revised since the WHI study: for healthy women beginning HRT before age 60 or within ten years of menopause onset, the bone protection benefit of HRT is accompanied by cardiovascular protection and cognitive benefit that substantially outweigh the risks in this population. Discuss with a physician experienced in evidence-based menopausal management.
“You build your bones between ages zero and thirty. After that, you protect what you built. Most people don’t start thinking about bone health until they’re already in the protection phase — and many start only after the first fracture.”
Bisphosphonate Therapy: What the Evidence Actually Supports
Bisphosphonates — alendronate, risedronate, zoledronic acid — reduce fracture risk in established osteoporosis and are an important component of management for patients with high fracture risk. They work by inhibiting osteoclastic bone resorption, reducing the rate of bone loss. However, bisphosphonate therapy is often prescribed mechanically without consideration of the significant nuances in evidence that affect when it is most beneficial, how long it should be continued, and what its limitations are.
The fracture risk reduction evidence is strongest at the hip and vertebral spine — the fractures with the worst mortality and morbidity consequences. The absolute risk reduction from bisphosphonate therapy depends on baseline fracture risk: in patients with T-score below -2.5 and prior fragility fracture, absolute risk reduction is clinically meaningful (NNT approximately 15 for vertebral fracture prevention over three years). In patients with osteopenia (T-score -1 to -2.5) and no prior fracture, absolute risk reduction is much smaller (NNT approaching 100+) and pharmaceutical treatment may not be warranted — lifestyle and nutritional interventions may provide equivalent risk reduction with no drug side effects.
Drug holiday: prolonged bisphosphonate use (beyond five years for oral agents, three years for IV zoledronic acid) is associated with a rare but serious complication — atypical femoral fractures from oversuppressed bone remodeling. The current evidence-based approach: after five years of oral bisphosphonate therapy in patients whose fracture risk has stabilized, a drug holiday of two to three years is appropriate while monitoring bone density and fracture risk markers. Patients at very high fracture risk (T-score below -3.0, multiple prior fractures) may benefit from continued therapy or transition to alternative agents. This detailed management requires regular reassessment, not indefinite automatic prescription refills.
The Gut-Bone Axis
Probiotics and bone density: several randomized trials have examined probiotic supplementation and bone markers. Nilsson et al. (Journal of Internal Medicine, 2018) found that Lactobacillus reuteri supplementation significantly reduced bone loss in older women compared to placebo over one year. The Probiotics in Postmenopausal Women (PROBIOME) trial showed significant attenuation of bone turnover markers with probiotic supplementation. The mechanisms — reduced intestinal inflammation, improved calcium absorption, vitamin K2 production — are biologically plausible. While the bone density evidence for probiotics is preliminary relative to the fracture prevention evidence for bisphosphonates, it supports including fermented foods and probiotic supplementation in a comprehensive bone health protocol as a low-risk adjunct.
The gut-bone axis also provides a mechanistic link between IBD, celiac disease, and bone loss beyond simple nutrient malabsorption: the gut dysbiosis and chronic intestinal inflammation in these conditions elevates systemic inflammatory cytokines (IL-1, IL-6, TNF-alpha) that increase RANKL expression and osteoclastic bone resorption. Treating the underlying inflammatory bowel condition reduces the inflammatory drive to bone resorption — another argument for comprehensive gut health management as a component of bone health protection.
Falls Prevention: The Other Half of Fracture Prevention
Fractures require both a bone fragile enough to break and a mechanical force sufficient to cause the break. Most hip fractures occur after falls. Falls prevention is therefore an equal partner to bone density maintenance in fracture prevention — and in older adults where falls are common, falls prevention interventions have strong evidence for reducing hip fracture incidence regardless of bone density.
Exercise interventions for falls prevention: balance training (yoga, tai chi, balance board exercises), lower extremity strengthening, and functional movement training all reduce fall risk. Sherrington et al. (Cochrane Database, 2019) meta-analyzed 108 trials and found that balance and functional exercise programs reduced falls by 24% in community-dwelling older adults. Strength training specifically reduces falls by 15-20% by preventing the stumble-recovery failure that converts near-falls into actual falls. The combination of bone density optimization through progressive resistance training and falls risk reduction through balance and functional training addresses both determinants of fracture risk simultaneously.
Medication review for fall risk is among the highest-value interventions in geriatric medicine. Psychotropic medications (benzodiazepines, antipsychotics, antidepressants), alpha blockers, and polypharmacy combinations that cause orthostatic hypotension are among the most powerful predictors of falls in older adults. A structured medication review by a clinical pharmacist in older adults with falls history has demonstrated fall risk reduction comparable to exercise interventions in multiple studies. Home hazard modification (removing trip hazards, improving lighting, installing grab bars) reduces environmental fall risk independently of physiological risk factors. The multifactorial nature of falls means that multifactorial intervention — exercise plus medication review plus environment modification — produces the largest absolute risk reduction.
Margaret’s Management After Comprehensive Assessment
Margaret’s new evaluation found vitamin D of 18 ng/mL, calcium intake of 600mg daily despite her calcium supplement (she had been taking calcium carbonate without food, reducing its absorption), PTH in the high-normal range (reflecting the secondary hyperparathyroidism driven by vitamin D deficiency), and PPI use for twenty years without ever having had a formal indication review — her original GERD had resolved years earlier but the medication had never been stopped. Vitamin D was corrected to 58 ng/mL. Dietary calcium was increased and the calcium supplement form changed to calcium citrate with meals. PPI was tapered and discontinued over four weeks with no significant GERD recurrence. Resistance training was initiated with a physical therapist specializing in osteoporosis.
Collagen peptides 10g daily and magnesium glycinate 400mg daily were added to her protocol. Alendronate was continued given her established osteoporosis. At two years, her DXA showed T-score improvement of 0.4 at the lumbar spine and 0.3 at the femoral neck — more improvement than bisphosphonate alone typically achieves, consistent with the additive benefit of nutritional optimization and resistance training. She has had no further fractures. The vertebral fracture she experienced was a painful, expensive, function-limiting event that the comprehensive protocol she now follows makes far less likely to recur. It came twenty years too late. But for the next twenty years — which is a realistic horizon for active management in a healthy sixty-six-year-old — it is exactly the right approach.
FAQ
Q: At what age should I start worrying about bone density?
The most important time for bone density optimization is childhood through age 25 — when 90-95% of peak bone mass is acquired. Exercise, calcium, vitamin D, and adequate protein during these years have the largest absolute impact on lifetime fracture risk. In adulthood, the goal shifts from building bone to maintaining what was built. Adults over 50 should have risk factor assessment for osteoporosis; DXA screening is recommended at 65 for women and 70 for men without risk factors, or earlier with risk factors (prior fragility fracture, long-term corticosteroid use, low body weight, smoking, family history). It’s never too early to start on prevention, but meaningful prevention can start at any age — including after an osteoporosis diagnosis.
Q: Is dairy necessary for bone health?
Dairy is the most efficient dietary calcium source but is not required. Non-dairy calcium sources can meet requirements if consumed in adequate quantities and diversity: canned salmon with bones, sardines, fortified plant milks (calcium-fortified oat milk provides comparable calcium to dairy per serving), bok choy, kale, broccoli, almonds, and calcium-set tofu. The practical challenge with non-dairy calcium is quantity — it requires more deliberate planning to consistently meet 1,000-1,200mg daily from plant sources. Monitoring dietary calcium intake against the target, with honest tracking of whether non-dairy sources actually achieve the target, prevents the common scenario where plant-based eaters believe they’re getting adequate calcium while falling significantly short.
Q: Does running damage bone or build it?
Running builds bone — the high-impact loading of running is strongly osteogenic. Runners have higher hip and spine bone density than sedentary individuals in cross-sectional studies. However, relative energy deficiency (RED-S), formerly called the female athlete triad, occurs in athletes with insufficient energy intake relative to expenditure — producing hormonal disruption that causes bone loss despite the osteogenic loading of running. Female distance runners with irregular menstruation or amenorrhea are at high fracture risk because the hormonal deficit overrides the mechanical loading stimulus. Adequate caloric intake and hormonal assessment in any female athlete with irregular periods or stress fractures is mandatory — running’s bone benefits are predicated on adequate energy availability.
Q: What is FRAX and should I use it?
FRAX (Fracture Risk Assessment Tool) is a validated model that calculates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors with or without DXA bone mineral density. It is the primary clinical tool for determining who meets the threshold for pharmaceutical treatment in patients with osteopenia (T-score -1 to -2.5). The FRAX score inputs include age, sex, BMI, prior fracture, parental hip fracture, smoking, alcohol, rheumatoid arthritis, secondary osteoporosis causes, and DXA T-score. Patients with FRAX 10-year hip fracture probability above 3% or major osteoporotic fracture probability above 20% generally meet treatment thresholds. A physician should be using FRAX to guide pharmaceutical treatment decisions — if alendronate has been recommended without discussing fracture risk assessment beyond just the T-score, reviewing the FRAX calculation together is a reasonable ask.
Q: Can I reverse osteoporosis once I have it?
Meaningful improvements in bone mineral density are achievable with comprehensive treatment — bisphosphonates typically increase BMD 5-8% over three years; anabolic agents (teriparatide, abaloparatide, romosozumab) achieve 10-15% BMD increases. Combined pharmaceutical treatment with resistance training and nutritional optimization can produce BMD improvements sufficient to reclassify a patient from osteoporosis to osteopenia on DXA. However, “reversing” osteoporosis in the sense of restoring full trabecular architecture that was lost is not currently achievable — once trabecular rods become plates and plates disconnect, the structural change is not fully reversible with current interventions. The goal is fracture risk reduction, not necessarily perfect BMD normalization — and meaningful fracture risk reduction is absolutely achievable with comprehensive management even in established osteoporosis.
Anabolic Agents: Beyond Bisphosphonates for Severe Osteoporosis
For patients with severe osteoporosis — T-score below -3.0, multiple prior fragility fractures, or very high 10-year FRAX fracture probability — the antiresorptive approach of bisphosphonates may be insufficient. Anabolic agents that stimulate new bone formation represent the most effective pharmaceutical interventions for rebuilding bone density in the highest-risk patients, and their availability and evidence base has expanded significantly in the past decade.
Teriparatide (PTH 1-34, Forteo) and abaloparatide (PTHrP analogue, Tymlos) stimulate osteoblast activity, increasing bone formation. They produce 10-15% increases in spine BMD and significantly greater fracture risk reduction than bisphosphonates in head-to-head trials in high-risk patients. The limitation: both are administered by daily subcutaneous injection, treatment duration is limited to 24 months (teriparatide) or 18 months (abaloparatide), and they are significantly more expensive than bisphosphonates. Following anabolic therapy with an antiresorptive agent (bisphosphonate or denosumab) is essential to maintain the bone gained — stopping without subsequent antiresorptive leads to rapid reversal of the BMD gains.
Romosozumab (Evenity) — a monoclonal antibody inhibiting sclerostin, a negative regulator of bone formation — is the most recently approved anabolic agent. It simultaneously stimulates bone formation AND inhibits resorption (a unique “dual effect”), producing the largest BMD gains of any available agent: approximately 13% spine BMD increase and 6% hip BMD increase over twelve months of monthly SC injection. Saag et al. (New England Journal of Medicine, 2017) demonstrated romosozumab was superior to alendronate for vertebral fracture reduction in high-risk postmenopausal women. Cardiovascular safety concerns (slightly higher serious cardiovascular event rates in one trial) limit its use to patients without prior MI or stroke. For patients with very high fracture risk and no cardiovascular contraindications, romosozumab followed by antiresorptive therapy produces the most dramatic fracture risk reduction of any sequential pharmaceutical approach currently available.
Exercise Prescription for Bone Health: Specificity Matters
Not all exercise builds bone equally. The specificity principle in exercise physiology applies to bone: bone responds to mechanical stress at the specific sites loaded, and the magnitude of the response depends on the magnitude, rate, and novelty of the load. Understanding which exercises produce the strongest osteogenic stimulus guides the design of a bone-protective exercise program.
The most osteogenic exercises produce high-magnitude forces through the skeleton, particularly at the sites most vulnerable to fracture (hip and spine). Multidirectional impact (jumping, hopping, impact sports) produces the highest bone-building stimulus at the hip. Axial loading through the spine (weighted squats, deadlifts, overhead press) produces the greatest spine bone stimulus. The LIFTMOR trial (Watson et al., Journal of Bone and Mineral Research, 2018) directly compared high-intensity resistance training (heavy deadlifts, squats, overhead press at 85-90% 1RM) versus standard exercise recommendations in postmenopausal osteopenic women — the high-intensity group achieved significant BMD gains at spine and hip while the control group did not. This is the most directly applicable evidence for resistance training intensity in osteoporosis management.
The implications for exercise prescription: low-intensity, high-repetition exercise (walking, light resistance bands, water aerobics) has minimal osteogenic stimulus, though it has other health benefits. The resistance training program that effectively builds bone requires progressive overload to loads that approach the maximum the individual can safely manage — not the light weights that many older adults default to out of fear of injury. Working with a physical therapist or strength coach experienced in osteoporosis can establish appropriate starting loads and a progression plan that achieves osteogenic stimulus safely. The fear that heavy lifting will fracture already-fragile bones is counterproductive — properly supervised progressive loading is protective, not harmful, even in established osteoporosis.
Bone Health Throughout the Lifespan
The different phases of bone health require different strategic emphases. Understanding which phase applies helps prioritize the interventions with the most impact at that life stage.
Childhood and adolescence (birth to 20): The bone-building phase. Maximum potential benefit from dietary and activity interventions. Priorities: adequate calcium from dairy and other sources (1,300mg daily during the adolescent growth spurt), sufficient vitamin D, which given how widespread deficiency is at this age generally means a supplement rather than an assumption, weight-bearing activity and sports participation (every year of active sports participation in adolescence adds to peak bone mass), and adequate protein and total caloric intake for growth support. The greatest missed opportunity in bone health: the adolescent girl who restricts her diet for weight concerns during the critical bone-building years, simultaneously reducing calcium, protein, and caloric intake while potentially suppressing estrogen from low body weight.
Adulthood (20-50): The maintenance phase. Priorities: maintaining the bone mass built during youth through regular weight-bearing and resistance exercise (at least 2-3 sessions weekly), continued adequate calcium and vitamin D, avoiding bone-robbing habits (smoking, excessive alcohol), and for women, supporting normal hormonal function (adequate body fat percentage, regular menstrual cycles, adequate caloric intake). Secondary prevention: monitoring bone density in high-risk adults (corticosteroid users, anyone with amenorrhea, patients with malabsorptive conditions) before significant bone loss has occurred.
Perimenopause and early postmenopause (45-65): The critical transition phase for women. Priorities: anticipating the accelerated bone loss of estrogen withdrawal; considering HRT discussion with a physician experienced in menopausal medicine; initiating or intensifying resistance training to partially compensate for the hormonal loss; ensuring vitamin D and calcium optimization; and establishing baseline DXA for monitoring. The five years immediately after menopause — when bone loss is fastest — are the most important time to have the HRT conversation and implement maximal lifestyle protection.
Later life (65+): The fracture prevention phase. Priorities: DXA screening and FRAX risk assessment; pharmaceutical treatment if threshold is met; falls prevention through balance training, medication review, and home modification; maintaining protein intake (often inadequate in older adults contributing to sarcopenia and impaired fracture healing); continued resistance training to maintain bone and muscle mass; and ensuring the social and environmental supports that enable continued physical activity.
The Twenty-Year Problem
Margaret’s fracture illustrates the consequence of a twenty-year window of missed intervention. Between ages forty-five and sixty-five, the specific interventions that would have preserved her bone density were available, evidence-supported, and relatively simple. The accelerated bone loss at menopause that produced her T-score of -2.8 at sixty-six had twenty years to develop without being assessed, without vitamin D optimization, without resistance training guidance, and while being accelerated by the PPI therapy that was never reviewed.
The population-level consequence of this pattern — treating osteoporosis reactively at fracture rather than proactively during the twenty years of modifiable risk — is over two million fractures annually in the United States, $57 billion in direct medical costs, and millions of individuals who lose independence, functional capacity, and in many cases their lives from a disease that is substantially preventable. The treatment for osteoporosis is not bisphosphonates. The treatment for osteoporosis is building and maintaining bone density throughout the life phases before fractures occur — and the tools to do this are dietary and lifestyle interventions that are accessible, affordable, and effective across the entire lifespan if applied during the relevant phase.
Starting now — regardless of age, regardless of current T-score — is better than starting later. The bone biology that responds to mechanical loading, vitamin D sufficiency, adequate calcium and protein, and hormonal optimization does not have a cutoff age above which intervention is futile. Margaret’s two-year BMD improvement demonstrates that even established osteoporosis responds to comprehensive management. But the best outcome is the one that never required a vertebral fracture to prompt the investigation that revealed decades of modifiable and unaddressed bone density risk.
Bone Density Testing: Getting the Most From Your DXA Scan
A DXA scan provides three measurements that require correct interpretation: T-score (comparison to peak young adult bone density), Z-score (comparison to age-matched and sex-matched peers), and bone mineral density in absolute terms (g/cm²). The T-score is used for osteoporosis diagnosis (T-score at or below -2.5). The Z-score helps identify patients whose bone density is lower than expected for their age — a Z-score below -2.0 suggests secondary causes are contributing to bone loss beyond normal aging, prompting investigation of the conditions listed earlier.
DXA limitations that affect interpretation: lumbar spine DXA is confounded by osteophytes (arthritic spurs that falsely elevate the density reading), aortic calcification, and vertebral deformities — the measured spine density in older adults with degenerative changes may be higher than the actual trabecular bone density. This is a meaningful error source: a patient with extensive osteophytes may appear to have acceptable lumbar spine density while having actually osteoporotic trabecular bone in the vertebral bodies. The hip DXA is less prone to these confounders and more reliably reflects fracture risk at the most clinically important site. When lumbar spine and hip results are discordant, the clinical picture and fracture history should guide management rather than average T-score.
The repeat DXA interval: DXA every two years is standard for patients on osteoporosis treatment or with significant bone loss risk. In patients in sustained stable remission on treatment with improving BMD, extending to three years is reasonable. Annual DXA is indicated only for very high-risk patients where rapid change is expected (initiation of high-dose corticosteroids, hyperparathyroidism, severe malabsorption). More frequent DXA does not improve outcomes and exposes patients to unnecessary radiation (though DXA radiation exposure is very low — comparable to a few hours of background radiation). The DXA interval should be matched to the clinical situation, not driven by administrative convenience or insurance coverage patterns.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map